Home
>
US Stocks
>
Royalty Pharma plc - Class A
Royalty Pharma plc - Class A
RPRX

Royalty Pharma plc - Class A

$37.683.14%

1D

1W

1M

1Y

3Y

5Y

Key Stats

Open
37
Today Low/High
36.84 / 38.15
52 Week Low/High
$34.41 / $52.82
Market Cap
$16.69B

Company Details

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and not-for-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry's leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma's current portfolio includes royalties on more than 45 commercial products, including AbbVie and J&J's Imbruvica, Astellas and Pfizer's Xtandi, Biogen's Tysabri, Gilead's HIV franchise, Merck's Januvia, Novartis' Promacta, and Vertex's Kalydeco, Orkambi, Symdeko and Trikafta, and five development-stage product candidates.
Organisation
Royalty Pharma plc - Class A
Headquaters
New York, New York, US
Employees
51
Industry
Health Technology

Discover more

Frequently Asked Questions

What is Royalty Pharma plc - Class A share price today

Can Indians buy Royalty Pharma plc - Class A shares?

How can I buy Royalty Pharma plc - Class A shares from India?

Can Fractional shares of Royalty Pharma plc - Class A be purchased?

What are the documents required to start investing in Royalty Pharma plc - Class A stocks?

We are a SEBI registered investement advisor